Clinical Trials Logo

Clinical Trial Summary

Single-sided deafness (SSD) refers to severe to profound sensorineural hearing loss on one side (average pure-tone hearing threshold≥70 dB HL at 0.5, 1, 2, and 4kHz) while the opposite side maintains normal hearing or mild hearing loss (30 dB HL). Asymmetrical hearing loss (AHL) refers to severe to profound sensorineural hearing loss in the bad ear (average pure-tone hearing threshold≥70 dB HL at 0.5, 1, 2, and 4kHz) and mild to moderate hearing loss in the contralateral ear. Moderate hearing loss (30≤mean pure-tone hearing threshold≤55dBHL). It is generally acknowledged that SSD is a particular clinical manifestation of AHL. The number of people who have hearing loss accounts for 5.3% of the total population, with children for 9%. According to the Second National Sampling Survey on Disabled Persons, China has 27.8 million people with hearing disabilities. The incidence of SSD adults in the United States is 7.2%, with 60,000 new cases per year, compared with 7,500 new patients with SSD annually in the UK. The incidence of SSD in neonates is 0.04%-0.34%, and it ranges from 0.1% to 0.5% in children and adolescents. The etiology of congenital SSD is primarily unknown, which is related to genes. Among the causes of acquired SSD, sudden deafness is the most common. Other causes include head trauma, Meniere's disease, labyrinthitis, unilateral acoustic neuroma, middle ear surgery, ototoxic drug exposure, Virus infection, noise-induced deafness, senile deafness, etc. SSD and AHL impede intellectual development and speech development in children and adolescents, which is associated with the side of hearing loss. For example, children with right-sided hearing loss have relatively poor language learning, logical thinking, and divergent thinking. In contrast, children with left-sided hearing loss have weaker analytical, comprehensive and visual memory abilities and relatively poor spatial imagination and visual-motor coordination. In addition, the lack of long-term monaural listening and sound source localization makes SSD children require excessive concentration, which is prone to fatigue and behavioral problems, and their academic performance is lower than that of normal children.


Clinical Trial Description

Current options for hearing interventions for patients with SSD are air conduction hearing aids, bone conduction hearing aids and cochlear implants. Attributed to the United States Food and Drug Administration (FDA) approval of one manufacturer's CI for patients aged five years and older with SSD in 2019, CI has been considered by the growing population. However, few studies on CI in patients with SSD, especially in China. Therefore, the study aims to evaluate the efficacy of CI in SSD patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05435612
Study type Interventional
Source Chinese PLA General Hospital
Contact Haiqiao Du, MD
Phone +86 18548921102
Email duhq2020@163.com
Status Recruiting
Phase N/A
Start date July 5, 2022
Completion date July 1, 2026

See also
  Status Clinical Trial Phase
Completed NCT03807713 - Clinical Study of Minimally Invasive Ponto Surgical Technique (MIPS) - Design Iteration N/A
Recruiting NCT04793412 - Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial N/A
Withdrawn NCT01264510 - Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) Phase 4
Completed NCT03281967 - Clinical Survey of Minimally Invasive Ponto Surgical Technique (MIPS) N/A
Recruiting NCT05775367 - Cochlear Implants in Young Children With SSD N/A
Completed NCT00201617 - Efficacy of the Bone-anchored Hearing Aid for Unilateral Deafness N/A
Completed NCT05379231 - Evaluation of BiCROS Fitting Benefits N/A
Completed NCT01715948 - Comparison of BAHA and CROS Hearing Aid in Single-Sided Deafness N/A
Terminated NCT00589407 - Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain N/A